Cargando…

CX3CL1 Overexpression Prevents the Formation of Lung Metastases in Trastuzumab-Treated MDA-MB-453-Based Humanized Tumor Mice (HTM)

SIMPLE SUMMARY: In about 15–18% of breast cancers the HER2 gene is amplified, which allows an anti-HER2 treatment. However, about 50% of HER2-positive patients experience de novo or acquired resistance to the antibody-based therapy with trastuzumab. Therefore, the identification of predictive marker...

Descripción completa

Detalles Bibliográficos
Autores principales: Wege, Anja Kathrin, Dreyer, Tobias F., Teoman, Attila, Ortmann, Olaf, Brockhoff, Gero, Bronger, Holger
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8158361/
https://www.ncbi.nlm.nih.gov/pubmed/34070094
http://dx.doi.org/10.3390/cancers13102459
_version_ 1783699870563958784
author Wege, Anja Kathrin
Dreyer, Tobias F.
Teoman, Attila
Ortmann, Olaf
Brockhoff, Gero
Bronger, Holger
author_facet Wege, Anja Kathrin
Dreyer, Tobias F.
Teoman, Attila
Ortmann, Olaf
Brockhoff, Gero
Bronger, Holger
author_sort Wege, Anja Kathrin
collection PubMed
description SIMPLE SUMMARY: In about 15–18% of breast cancers the HER2 gene is amplified, which allows an anti-HER2 treatment. However, about 50% of HER2-positive patients experience de novo or acquired resistance to the antibody-based therapy with trastuzumab. Therefore, the identification of predictive markers for therapy success and novel combination strategies is needed. Here we explored the impact of CX3CL1 on trastuzumab treatment efficiency and immunological mechanism involved in a humanized tumor mouse model. Trastuzumab treatment showed pronounced efficiency in CX3CL1 overexpressing cancer cells compared to low expressing cells preventing lung metastasis, while the administration of CX3CL1 shedding inhibition did not cause an enhanced treatment effect. Moreover, the application of shedding inhibitors to CX3CL1 overexpression tumors resulted in a slightly enhanced tumor growth. Therefore, the presence of CX3CL1 might predict a pronounced response to trastuzumab therapy in patients and should be investigated in a large cohort of HER2(+) patients. ABSTRACT: CX3CL1 is a multifunctional chemokine that is involved in numerous biological processes, such as immune cell attraction and enhanced tumor immune cell interaction, but also in enhancing tumor cell proliferation and metastasis. The multifarious activity is partially determined by two CX3CL1 isoforms, a membrane-bound and a soluble version generated by proteolytic cleavage through proteases. Here, we investigated the impact of CX3CL1 overexpression in MDA-MB-453 and SK-BR-3 breast cancer cells. Moreover, we evaluated the therapeutic capacity of Matrix-Metalloproteinases-inhibitors TMI-1 and GI254023X in combination with the anti-HER2 antibody trastuzumab in vitro and in vivo. TMI-1 and GI254023X caused a reduced shedding of CX3CL1 and of HER2 in vitro but without effects on tumor cell proliferation or viability. In addition, trastuzumab treatment did not retard MDA-MB-453 cell expansion in vitro unless CX3CL1 was overexpressed upon transfection (MDA-MB-453(CX3CL1)). In humanized tumor mice, which show a coexistence of human tumor and human immune system, CX3CL1 overexpression resulted in a slightly enhanced tumor growth. However, trastuzumab treatment attenuated tumor growth of both MDA-MB-453(CX3CL1) and empty vector transfected MDA-MB-453 transplanted mice but showed enhanced efficiency especially in preventing lung metastases in CX3CL1 overexpressing cancer cells. However, TMI-1 did not further enhance the trastuzumab treatment efficacy.
format Online
Article
Text
id pubmed-8158361
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-81583612021-05-28 CX3CL1 Overexpression Prevents the Formation of Lung Metastases in Trastuzumab-Treated MDA-MB-453-Based Humanized Tumor Mice (HTM) Wege, Anja Kathrin Dreyer, Tobias F. Teoman, Attila Ortmann, Olaf Brockhoff, Gero Bronger, Holger Cancers (Basel) Article SIMPLE SUMMARY: In about 15–18% of breast cancers the HER2 gene is amplified, which allows an anti-HER2 treatment. However, about 50% of HER2-positive patients experience de novo or acquired resistance to the antibody-based therapy with trastuzumab. Therefore, the identification of predictive markers for therapy success and novel combination strategies is needed. Here we explored the impact of CX3CL1 on trastuzumab treatment efficiency and immunological mechanism involved in a humanized tumor mouse model. Trastuzumab treatment showed pronounced efficiency in CX3CL1 overexpressing cancer cells compared to low expressing cells preventing lung metastasis, while the administration of CX3CL1 shedding inhibition did not cause an enhanced treatment effect. Moreover, the application of shedding inhibitors to CX3CL1 overexpression tumors resulted in a slightly enhanced tumor growth. Therefore, the presence of CX3CL1 might predict a pronounced response to trastuzumab therapy in patients and should be investigated in a large cohort of HER2(+) patients. ABSTRACT: CX3CL1 is a multifunctional chemokine that is involved in numerous biological processes, such as immune cell attraction and enhanced tumor immune cell interaction, but also in enhancing tumor cell proliferation and metastasis. The multifarious activity is partially determined by two CX3CL1 isoforms, a membrane-bound and a soluble version generated by proteolytic cleavage through proteases. Here, we investigated the impact of CX3CL1 overexpression in MDA-MB-453 and SK-BR-3 breast cancer cells. Moreover, we evaluated the therapeutic capacity of Matrix-Metalloproteinases-inhibitors TMI-1 and GI254023X in combination with the anti-HER2 antibody trastuzumab in vitro and in vivo. TMI-1 and GI254023X caused a reduced shedding of CX3CL1 and of HER2 in vitro but without effects on tumor cell proliferation or viability. In addition, trastuzumab treatment did not retard MDA-MB-453 cell expansion in vitro unless CX3CL1 was overexpressed upon transfection (MDA-MB-453(CX3CL1)). In humanized tumor mice, which show a coexistence of human tumor and human immune system, CX3CL1 overexpression resulted in a slightly enhanced tumor growth. However, trastuzumab treatment attenuated tumor growth of both MDA-MB-453(CX3CL1) and empty vector transfected MDA-MB-453 transplanted mice but showed enhanced efficiency especially in preventing lung metastases in CX3CL1 overexpressing cancer cells. However, TMI-1 did not further enhance the trastuzumab treatment efficacy. MDPI 2021-05-18 /pmc/articles/PMC8158361/ /pubmed/34070094 http://dx.doi.org/10.3390/cancers13102459 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Wege, Anja Kathrin
Dreyer, Tobias F.
Teoman, Attila
Ortmann, Olaf
Brockhoff, Gero
Bronger, Holger
CX3CL1 Overexpression Prevents the Formation of Lung Metastases in Trastuzumab-Treated MDA-MB-453-Based Humanized Tumor Mice (HTM)
title CX3CL1 Overexpression Prevents the Formation of Lung Metastases in Trastuzumab-Treated MDA-MB-453-Based Humanized Tumor Mice (HTM)
title_full CX3CL1 Overexpression Prevents the Formation of Lung Metastases in Trastuzumab-Treated MDA-MB-453-Based Humanized Tumor Mice (HTM)
title_fullStr CX3CL1 Overexpression Prevents the Formation of Lung Metastases in Trastuzumab-Treated MDA-MB-453-Based Humanized Tumor Mice (HTM)
title_full_unstemmed CX3CL1 Overexpression Prevents the Formation of Lung Metastases in Trastuzumab-Treated MDA-MB-453-Based Humanized Tumor Mice (HTM)
title_short CX3CL1 Overexpression Prevents the Formation of Lung Metastases in Trastuzumab-Treated MDA-MB-453-Based Humanized Tumor Mice (HTM)
title_sort cx3cl1 overexpression prevents the formation of lung metastases in trastuzumab-treated mda-mb-453-based humanized tumor mice (htm)
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8158361/
https://www.ncbi.nlm.nih.gov/pubmed/34070094
http://dx.doi.org/10.3390/cancers13102459
work_keys_str_mv AT wegeanjakathrin cx3cl1overexpressionpreventstheformationoflungmetastasesintrastuzumabtreatedmdamb453basedhumanizedtumormicehtm
AT dreyertobiasf cx3cl1overexpressionpreventstheformationoflungmetastasesintrastuzumabtreatedmdamb453basedhumanizedtumormicehtm
AT teomanattila cx3cl1overexpressionpreventstheformationoflungmetastasesintrastuzumabtreatedmdamb453basedhumanizedtumormicehtm
AT ortmannolaf cx3cl1overexpressionpreventstheformationoflungmetastasesintrastuzumabtreatedmdamb453basedhumanizedtumormicehtm
AT brockhoffgero cx3cl1overexpressionpreventstheformationoflungmetastasesintrastuzumabtreatedmdamb453basedhumanizedtumormicehtm
AT brongerholger cx3cl1overexpressionpreventstheformationoflungmetastasesintrastuzumabtreatedmdamb453basedhumanizedtumormicehtm